(redirected from gene alteration)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.

MUTATION, French law. This term is synonymous with change, and is particularly applied to designate the change which takes place in the property of a thing in its transmission from one person to another; permutation therefore happens when, the owner of the thing sells, exchanges or gives it. It is nearly synonymous with transfer. (q.v.) Merl. Repert. h.t.

References in periodicals archive ?
The p53 GeneChip has been compared with direct sequencing for identifying p53 gene alterations in DNA extracted from frozen tissue of 108 ovarian cancers.
It is accepted that gene alterations could change the identity of a person or even the identity of the human race.
Our pre-clinical pipeline is strong in both pharmaceuticals and our gene alteration technology.
SCI's gene alteration panel, developed in partnership with CellNetix Pathology & Laboratories, is based on a focused set of gene alterations that are most relevant to cancer treatments.
Nasdaq:NPRO) today announced that it has in-licensed gene alteration technology from the University of Delaware and Thomas Jefferson University.
Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project and Memorial Sloan-Kettering Cancer Center discover first gene alteration associated with patient age and neuroblastoma outcome
NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced findings from a new study of the largest panel of thyroid cancer-associated gene alterations to date.
Additionally, more than half of the MpBC cases were found to have gene alterations and/or loss of PTEN in the PI3K pathway, an area in which several experimental therapies are being investigated in clinical trials.
1,3) Oxygen and nitrogen free radicals bind target DNA, RNA, proteins, or lipid, (44,45) resulting in gene alterations, genetic instability, and aberrant methylation.
cystic fibrosis), as well as three gene alterations that have pharmacogenetic implications.
The present study undertaken on freshly operated tumour tissues (n=50) and corresponding peripheral blood samples (n=50) of the ovarian cancer patients as well as the peripheral blood samples collected from 50 normal healthy individuals (control) was designed to determine the involvement of p16INK4A gene alterations in the human ovarian cancers.
Although the biological alterations needed to reach this goal are still highly complex (the same as those facing the intelligent designer), the scientist running a directed evolution experiment does not need to think at all about the individual gene alterations that are required.